Anxiety and Alcohol Use Disorders

Pandey, Subhash C.

doi:10.1016/b978-0-12-405941-2.00022-5

Cited by 4 publications

(2 citation statements)

References 194 publications

(260 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 7 , 8 This propensity of alcohol and mental health condition has been mechanistically explained using the same pathways both in human and animal studies. 9 - 11 Alcohol intake in excessive amounts could also adversely impact the prognosis in these conditions. 12 , 13 Among the clinical trials conducted to date, Quetiapine has been shown to have positive effects on alcohol consumption—increased days of abstinence from alcohol during the two to seven months of treatment 14 ; increased abstinent days and improvement in depression, anxiety, and insomnia 15 ; and increased abstinent days and fewer hospitalizations in alcohol-dependent patients with disturbed sleep.…”

Section: Introductionmentioning

confidence: 99%

Interaction of Heavy Drinking Patterns and Depression Severity Predicts Efficacy of Quetiapine Fumarate XR in Lowering Alcohol Intake in Alcohol Use Disorder Patients

et al. 2020

View full text Add to dashboard Cite

Background: Shared etiological pathways of dopamine and serotonin neurotransmission play a central role in heavy alcohol intake and exacerbation in the symptoms of depression. We investigated the treatment efficacy of Quetiapine fumarate extended release (XR) in lowering alcohol intake in alcohol use disorder (AUD) patients indicated by the shared alleviation of depression ratings and patterns of heavy drinking. Methods: Hundred and eight male and female heavy drinking AUD patients in the age range of 18 to 64 years. participated in a randomized clinical trial (RCT) to receive 12 weeks of quetiapine XR or placebo (N = 115). Participants were sub-grouped by the severity grading of depression using Montgomery-Asberg Depression Rating Scale (MADRS) (clinically relevant ⩾8 [CR], clinically non-relevant ⩽7 [CNR]) at baseline in both the groups. Drinking history and depression ratings were assessed at the patients’ visits. Results: Heavy drinking days (HDD) and total drinks (TD) were significantly fewer in CR patients at the treatment end. A true positive response in AUROC analysis supported the lowering of TD in CR patients. The number of drinking days (NDD) and average drinks per drinking day (AvgD) were lower in the CNR patients at treatment-end. Significant associations with increasing effect sizes were observed for all the heavy drinking measures (HDD, TD, NDD, and AvgD) and MADRS scores by the end of the treatment course. Conclusions: Baseline elevated depressive symptoms could likely predict the course of heavy alcohol drinking during the treatment, and efficacy outcome of a treatment. AUD patients with baseline clinically significant depression had a progressive lowering in heavy drinking markers significantly corresponding to the lowering of depression symptoms by the end of treatment with Quetiapine fumarate XR. ClinicalTrials.gov: NCT#0049862 ( https://clinicaltrials.gov/ct2/show/NCT00498628?term=litten&draw=2&rank=3 )

show abstract

Section: Introductionmentioning

confidence: 99%

Interaction of Heavy Drinking Patterns and Depression Severity Predicts Efficacy of Quetiapine Fumarate XR in Lowering Alcohol Intake in Alcohol Use Disorder Patients

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This propensity of alcohol and mental condition has been mechanistically explained using the same pathways both in human and animal studies. 9-11 Alcohol intake in excessive amounts could also adversely impact the prognosis in these conditions. 12,13 Among the clinical trials conducted to date, Quetiapine has been shown to have positive effects on alcohol consumption--increased days of abstinence from alcohol during the 2–7 months of treatment 14 ; increased abstinent days and improvement in depression, anxiety, and insomnia 15 ; and increased abstinent days and fewer hospitalizations in alcohol-dependent patients with disturbed sleep.…”

Section: Introductionmentioning

confidence: 99%

Interaction of Heavy Drinking Patterns and Depression Severity predicts Efficacy of Quetiapine Fumarate XR in lowering Alcohol Intake in Alcohol Use Disorder Patients

Vatsalya

Kong

Marsano

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Shared etiological pathways of dopamine and serotonin neurotransmission play a central role in heavy alcohol intake and exacerbation in the symptoms of depression. We investigated the role of depression ratings and patterns of heavy drinking on the treatment efficacy of Quetiapine fumarate XR in lowering alcohol intake in alcohol use disorder (AUD) patients. Methods: One hundred and eight male and female heavy drinking AUD patients in the age range of 18 to 64 yrs. received 12 weeks of active treatment. Participants were grouped by the severity grading of depression using Montgomery Asberg Depression Rating Scale (MADRS) (clinically relevant≥8 [CR], clinically non-relevant≤7 [CNR]) at baseline. Drinking history and depression ratings were assessed at the patients visits. Results: Heavy drinking days (HDD) and total drinks (TD) were significantly fewer in CR patients at the treatment end. A true positive response in AUROC analysis supported the lowering of TD in CR patients. The number of drinking days (NDD) and average drinks per drinking day (AvgD) were lower in the CNR patients at treatment-end. Significant associations with increasing effect sizes were observed for all the heavy drinking measures (HDD, TD, NDD and AvgD) and MADRS scores by the end of the treatment course. Conclusions: Baseline elevated depressive symptoms could likely predict the course of heavy alcohol drinking during the treatment, and efficacy outcome of a treatment. AUD patients with baseline clinically significant depression had a progressive lowering in heavy drinking markers significantly corresponding to the lowering of depression symptoms by the end of treatment with Quetiapine fumarate XR.

show abstract

Gene Targeting Studies of Hyperexcitability and Affective States of Alcohol Withdrawal in Rodents

Greenberg

Crabbe

2016

International Review of Neurobiology

View full text Add to dashboard Cite

Anxiety and Alcohol Use Disorders

Cited by 4 publications

References 194 publications

Interaction of Heavy Drinking Patterns and Depression Severity Predicts Efficacy of Quetiapine Fumarate XR in Lowering Alcohol Intake in Alcohol Use Disorder Patients

Interaction of Heavy Drinking Patterns and Depression Severity Predicts Efficacy of Quetiapine Fumarate XR in Lowering Alcohol Intake in Alcohol Use Disorder Patients

Interaction of Heavy Drinking Patterns and Depression Severity predicts Efficacy of Quetiapine Fumarate XR in lowering Alcohol Intake in Alcohol Use Disorder Patients

Gene Targeting Studies of Hyperexcitability and Affective States of Alcohol Withdrawal in Rodents

Contact Info

Product

Resources

About